Q-omics provides the consensus-scored VPS26B profile across patient tissues and cancer cell-line models. VPS26B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, VPS26B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, VPS26B protein abundance shows 23,096 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, KIRC, and GBM as cancer lineages where VPS26B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS26B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS26B survival associations across molecular data types. VPS26B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS26B RNA expression–survival associations across cancer types. High VPS26B expression shows unfavorable associations in KICH, ACC, MESO and LUSC, but favorable associations in UCEC and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for VPS26B RNA expression.
This table summarizes VPS26B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for VPS26B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS26B shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, LUAD, LUSC and CHOL. The KIRC box plot shows higher VPS26B RNA expression in tumor versus normal tissue (log2 FC = +0.512, t-test p < 0.001).
This table shows molecular features associated with VPS26B in patient tissues and cancer cell lines. In patient samples, VPS26B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS26B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
